Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study

Table 2 Reference population mean and Study Participants C _min and C _max by antiretroviral drug

					C _min		C _max
Antiretroviral agent*	Reference	Dose (mg)	Freq	N	Population mean (ug/mL)	Study participants median (IQR)	Population mean (ug/mL)	Study participants median (IQR)
Atazanavir**	[33]	400	QD	9	273	214 (95–373)	3152	1870 (979–2950)
Atazanavir** boosted with ritonavir	[33]	300	QD	18	862	835 (663–1220)	5233	3430 (2670–4450)
Lopinavir boosted with ritonavir	[34]	400	BID	16	5500	6660 (4360–7710)	9800	8420 (7240–11600)
Lopinavir boosted with ritonavir	[34]	800	QD	4	1700	6445 (2452–8260)	11800	11685 (7403–14900)
Efavirenz	[35]	600	QD	16	1768	1680 (1180–3450)	4072	3235 (2330–5180)
Nevirapine	[36]	200	BID	11	3730	5270 (3380–7190)	5740	5510 (4810–7860)
Nevirapine	[36]	400	QD	8	2880	5995 (2590–7275)	6690	6400 (4838–9380)

QD, once daily; BID, twice daily; IQR, interquartile range.
*Nucleos(t)ide backbone: of 9 participants on Atazanavir 400 mg QD, all 9 were taking Abacavir/3TC; of 18 participants on Atazanavir/ritonavir 300 mg/100 mg QD, 11 were taking Abacavir/3TC, 3 Tenofivir/FTC, 3 Tenofivir/3TC and 1 Zidovudine/3TC; of 16 participants on Lopinavir/ritonavir 400 mg/100 mg BID, 7 were taking Zidovudine/3TC, 6 Abacavir/3TC, 1 Tenofivir/FTC, 1 Tenofivir/3TC and 1 was on PI monotherapy; of 4 participants on Lopinavir/ritonavir 800 mg/200 mg QD, 2 were taking Tenofivir/FTC, 1 Abacavir/3TC, 1 Didanosine/3TC; of 16 participants on Efavirenz 600 mg QD, 5 were taking Tenofivir/FTC, 5 Abacavir/3TC, 5 Zidovudine/3TC, 1 Tenofovir/3TC; of 11 participants on Nevirapine 200 mg BID, 7 were taking Zidovudine/3TC, 4 Abacavir/3TC; of 8 participants on Nevirapine 400 mg/ QD, 4 were taking Abacavir/3TC, 1 Tenofivir/FTC, 1 Zidovudine/3TC, 1 Tenofivir/3TC, 1 Didanosine/3TC.
** Of the 27 particpants taking Atazanavir or Atazanvir/ritonavir, none were taking any gastric acid suppression medication.

ISSN: 1471-2334